VVUS VIVUS Inc

VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August 7, 2018. The company will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT the same day to review results and provide a business update.

To listen via webcast, please visit http://ir.vivus.com/ or by clicking here.

To listen via phone, please use the dial in information provided below.

Dial in Details:Toll-Free: (877) 359-2916       International: (224) 357-2386  Passcode: 7977356

A webcast replay will be available on the VIVUS website for 30 days.

About VIVUSVIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs..  For more information about the Company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2017 as filed on March 14, 2018, and as amended by the Form 10-K/A filed on April 26, 2018, and periodic reports filed with the Securities and Exchange Commission.

CONTACT:
VIVUS, Inc.	Investor Relations
Mark Oki	Lazar Partners
Chief Financial Officer	David Carey
oki@vivus.com	dcarey@lazarpartners.com
650-934-5200	212-687-1768